Vascular endothelial growth factor-A and Poly(A) binding protein-interacting protein 2 expression in human head and neck carcinomas: correlation and prognostic significance by Onesto, C et al.
Vascular endothelial growth factor-A and Poly(A) binding protein-
interacting protein 2 expression in human head and neck
carcinomas: correlation and prognostic significance
C Onesto*,1, J-M Hannoun-Le ´vi
1,2, E Chamorey
3, J-L Formento
4, A Ramaioli
3 and G Page `s
1
1Institute of Signalling, Developmental Biology and Cancer Research, CNRS – UMR 6543, University of Nice Sophia-Antipolis (Equipe labellise ´e Ligue
Nationale Contre le Cancer), 33 avenue de Valombrose, 06189 Nice Cedex, France;
2Department of Radiation Oncology, Antoine Lacassagne anti-
Cancer Centre, 33 avenue de Valombrose, 06189 Nice Cedex, France;
3Department of statistics, Antoine Lacassagne anti-Cancer Centre, 33 avenue de
Valombrose, 06189 Nice Cedex, France and
4Department of Oncopharmacology, Antoine Lacassagne anti-Cancer Centre, 33 avenue de Valombrose,
06189 Nice Cedex, France
Vascular endothelial growth factor-A (VEGF-A) has been demonstrated to play an important role in tumour angiogenesis and to
influence prognosis in many cancers. However its prognostic value in head and neck squamous cell carcinomas (HNSCCs) remains
controversial. Therefore, we investigated the clinical relevance of VEGF-A expression in HNSCCs and analysed whether its
expression was associated with PAIP2 protein levels, a VEGF-A mRNA-binding partner that strongly regulates VEGF-A expression in
tissue culture. We determined the correlation of VEGF-A and PAIP2 protein levels, quantitatively evaluated in tumour tissue
homogenates from 54 patients with HNSCC, to clinicopathological parameters. We showed that VEGF-A expression in HNSCC is
correlated to the stage of tumour differentiation (P¼0.050) and is an independent prognostic factor for progression-free survival
(P¼0.001) and overall survival (P¼0.0004). In a pharynx carcinoma cell line, we demonstrated by RNA interference that VEGF-A
expression is closely controlled by PAIP2. Moreover, in human HNSCCs, VEGF-A expression is significantly correlated to PAIP2
protein levels (P¼0.0018). Nevertheless, PAIP2 expression is associated with neither clinicopathological factors nor patient’s survival.
Our data suggest that, in contrast to PAIP2 protein levels, which are unrelated to tumour prognosis, VEGF-A expression could serve
as a prognostic marker in head and neck cancer and may be helpful for targeted therapies.
British Journal of Cancer (2006) 94, 1516–1523. doi:10.1038/sj.bjc.6603108 www.bjcancer.com
Published online 25 April 2006
& 2006 Cancer Research UK
Keywords: vascular endothelial growth factor-A; Poly(A) binding protein-interacting protein 2; head and neck carcinoma; human
tumour specimens; prognostic value
                                                       
Head and neck cancer, including oral cancer, is the sixth most
common type of human cancer, with an annual incidence of more
than 500000 cases worldwide. Smoking and alcohol abuse are the
two major contributing factors of this disease. Head and neck
squamous cell carcinoma (HNSCC) is the most common and the
most aggressive type of head and neck tumour. Head and
necksquamous cell carcinoma includes cancers arising from the
oral cavity, pharynx (oro- and hypo-) and larynx. Despite major
advances in cellular and molecular biology of cancer, as well as in
therapeutic strategies, the survival rate for head and neck cancer,
and particularly for HNSCC, has not improved in the last 30 years,
with a 5-year overall survival rate of approximately 50% (Mao et al,
2004). Like most epithelial cancers, HNSCC develops through the
accumulation of multiple genetic and epigenetic alterations, such
as deletion of tumour suppressor regions, mutations, de novo
promoter methylation of tumour suppressor genes, and amplifica-
tion or overexpression of oncogenes (Mao et al, 2004). While early
stage head and neck tumours can be successfully treated with
surgery, the treatment of patients presented with an advanced
stage using combined therapies (surgery followed or not by
radiotherapy or radiochemotherapy alone) does not achieve good
local control and overall survival. Development of multiple
primary tumours, as well as tumour recurrences, are major causes
of treatment failure. Moreover, there is no specific molecular
marker currently used routinely to predict the clinical behaviour of
head and neck cancer. In recent years, several studies have
characterised changes in gene-expression in HNSCCs compared
with normal oral mucosa. Some molecular markers have been
identified and correlated with poor prognosis, such as p53, cyclin
D1 or epidermal growth factor receptor (EGFR) (Hunter et al,
2005). Markers related to tumour neovascularisation could also
predict the outcome in head and neck cancer patients. To grow
beyond a microscopic size, most tumours must initiate angio-
genesis (Folkman, 2002). One of the key angiogenic factors is the
vascular endothelial growth factor-A (VEGF-A), which promotes
tumour neovascularisation. In HNSCC, VEGF-A is considered to
be a leading candidate of tumour angiogenesis, exhibiting its effect
on the vasculature in paracrine and probably autocrine patterns
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s(Kyzas et al, 2005b). Furthermore, VEGF-A has been described as
an important prognostic factor in many types of human cancers
(Dvorak, 2002). Several retrospective studies in HNSCC have
demonstrated that VEGF-A expression is associated with clinico-
pathological factors and/or poor patient’s outcome, suggesting that
VEGF-A could serve as a prognostic marker (Eisma et al, 1997;
Maeda et al, 1998; Mineta et al, 2000; Smith et al, 2000; Lim et al,
2003; Kimura et al, 2004; Uehara et al, 2004; Kyzas et al, 2005b).
However, the status of VEGF-A remains unclear since other
HNSCC retrospective studies have shown no correlation between
VEGF-A expression and tumour prognosis (Salven et al, 1997; Tae
et al, 2000; Do et al, 2004; Schimming et al, 2004). These
conflicting results may be due partly to the method of detection of
VEGF-A expression (ie immunohistochemistry), used in most of
the previous reports, and which is a semiquantitative method.
Therefore, we proposed to quantitatively evaluate the prognostic
significance of VEGF-A protein levels in HNSCC, using an ELISA.
Moreover, we have recently demonstrated in several tumour cell
lines that VEGF-A expression is highly regulated by an RNA-
binding and stabilizing partner of the VEGF-A mRNA, the Poly(A)
binding protein-interacting protein 2 (PAIP2) (Onesto et al, 2004).
Thus, we investigated in the present study whether VEGF-A
expression is associated with PAIP2 expression in HNSCC and
examined whether PAIP2 expression is related to clinicopatholo-
gical parameters and patient’s survival.
PATIENTS AND METHODS
Patients
This retrospective study includes a total of 54 patients diagnosed
with an HNSCC between January 2000 and March 2002 at the
Antoine Lacassagne anti-Cancer Centre (Nice, France), and for
whom both tumour specimens (obtained from the primary tumour
and immediately frozen in liquid nitrogen after excision) and
clinical outcomes were available. All patients were treated and
followed-up at this same institution. All tumour specimens
obtained with informed consent, come from either surgical
excision during total tumour removal or endoscopic examination
performed at the time of diagnosis. Hence, all patients were fresh
cases and had not received any previous treatment. Patient
characteristics are summarised in Table 1. Briefly, with a median
follow-up of 25 months (1–62), this study analysed 54 patients
(sex ratio M/F¼2.4) with a median age at diagnosis of 57 (43–75)
and 63 (29–86) for male and female, respectively. Anatomic sites
were oral cavity (39%), pharynx (oro- and hypo-, 43%) and larynx
(18%). Most of patients were classified T3–T4 (T1–T2 31%, T3–
T4 69%), presented with positive cervical lymph nodes (N0 33%,
Nþ 67%) and tumour with high/moderate differentiation grade
(high/moderate 60%, low 40%). For statistical analysis, we grouped
T and N stages as follows: T1–T2 and T3–T4, as well as N0 (node
negative) and Nþ (¼N1þN2þN3; node positive). Treatment
policy for early stage tumours (T1–T2) was either surgery,
associated or not with post-operative radiation therapy, or
radiotherapy alone. Locally advanced stage tumours (T3–T4)
were treated with concomitant regimen associating radiotherapy
plus chemotherapy (total dose of 70Gy in 35 fractions over 7
weeksþ5FU 750mgm
 2 d1-5 cycle 1, thereafter 430mgm
 2 d1-5
cycles 2 and 3 associated with CDDP 100mgm
 2 d1 of each cycle)
(Calais et al, 1999). Patients presenting with cervical lymph node
involvement after surgery received preferentially a postoperative
radiotherapy, associated sometimes with concomitant chemo-
therapy (especially for patients treated after 2001, for whom
several of them have been included in a clinical trial (Bernier et al,
2004)). For each patient, post-treatment surveillance was performed
every 3 months. Clinical and endoscopic exams were achieved
alternatively by head and neck surgeon and radiation oncologist.
CT-scans associated or not with magnetic resonance imaging of
the cervical area were performed at the time of each clinical
examination during the first year post-treatment and every 6
months afterwards. Bone scan, chest, abdominal or cerebral CT-
scans were performed in case of distant metastatic disease
suspicion.
Cell line and culture conditions
The human pharynx carcinoma cell line Detroit 562 was from
American Type Culture Collection. Cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) (Life Technologies, Inc.)
supplemented with 7.5% heat-inactivated fetal calf serum.
Preparation of cytosolic extracts from tumour tissues
Tumour specimens immediately frozen after surgical excision were
mechanically pulverised in liquid nitrogen. The resulting powders
were homogenised with a Polytron PT-1020 in Tris-HCl buffer, pH
7.4, containing EDTA 1mM, dithiothreitol 0.5mM, sodium
molybdate 10mM and inhibitors of proteases and phosphatases
and centrifuged at 105000  g for 1h to obtain cytosols that were
stored at  801C until analysis for PAIP2 and VEGF-A expression
levels.
Table 1 Characteristics of 54 patients with head and neck squamous cell
carcinomas
Characteristics # %
Male 38 70
Female 16 30
Median age at diagnosis (y)
Male 57 (43–75)
Female 63 (29–86)
Median follow-up (mo) 25 (1–62)
Anatomic sites
Oral cavity 21 39
Oropharynx 14 26
Hypopharynx 9 17
Larynx 10 18
Clinical stage
Tl 4 7
T2 13 24
T3 12 22
T4 25 47
Nodal status
NO 18 33
N1 4 7
N2 29 54
N3 3 6
Differentiation stage
a
High 14 26
Moderate 18 34
Low 21 40
Treatment
S1 4 2 6
RT 5 9
CT+RT 16 30
S+RT 10 18
S+RT+CT 9 17
aFor one patient the information was not available. y: years, mo: months, CT:
chemotherapy, RT: radiotherapy, S: surgery.
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The following 21-mer oligoribonucleotides and their reverse
sequence were synthesised by Eurogentec (Liege, Belgium). Four
independent small_interfering RNA (siRNAs) were designed in
different regions of human PAIP2 complete cDNA (NCB #
Accession NM_016480). The respective sequences are the follow-
ing:
PAIP2 (1): 50-GGCUCUUCUCUGGAAGAUCTT-30;
PAIP2 (2): 50-GAUCUUGUGGUCAAGAGCATT-30;
PAIP2 (3): 50-UCAUGAAGAUGACAAUCCATT-30
PAIP2 (4): 50-CGACAACCAACAUCAGCCATT-30.
The siRNA sequence targeting the EGFP coding sequence (NCB
# Accession AF323988) was used as an irrelevant siRNA and is the
following: 50-GAACGGCAUCAAGGUGAACTT-30.
Detroit 562 cells were transiently transfected with siRNA as
previously described (Onesto et al, 2004). At 48h following the
second transfection, cells were lysed and analysed either by
Western blotting for PAIP2 expression or by Northern blotting for
VEGF-A mRNA expression. In parallel, tissue culture supernatants
were collected and tested by immunoassay for secreted VEGF-A
expression.
Northern blotting
Cells were lysed in Trizol Reagent buffer (GIBCO BRL, Cergy-
Pentoise, France). RNA was prepared according to the manufac-
turer’s protocol. RNA (20) mg was used for Northern blotting
analysis of PAIP2 and VEGF-A mRNA expression as previously
described (Onesto et al, 2004).
Western blotting
50mg of whole cell extracts from Detroit 562 cells or cytosolic
extracts from tumour homogenates were subjected to Western
blotting using a homemade polyclonal anti-PAIP2 antibody (1/
2000) (Onesto et al, 2004). Bound antibody was detected using the
CDP-star system (New England Biolabs, Beverly, MA, USA).
The expression levels of b-actin or extracellular signals-
regulated kinase 2 (ERK2), used as loading controls, have also
been monitored using a monoclonal anti-b-actin antibody (1/8000)
(clone AC-15, Sigma, Saint-Quentin-Fallaviers, France) or a
polyclonal anti-ERK2 antibody (1/5000) (homemade), respectively.
The level of PAIP2 for each tumour sample was quantified
with a GeneGnome chemiluminescent imaging system (Syngene,
Frederick, MD, USA) and normalised to the signal for b-actin as
well as to the signal for PAIP2 in HeLa cell extracts run in parallel
on each blot. The latter represents an internal control which rules
out any variation between the different blots.
ELISA assay
VEGF-A concentration of cytosolic extracts from tumour speci-
mens and of tissue culture supernatants were determined using the
Quantikine Human VEGF-A Immunoassay system, following the
manufacturer’s guidelines (R&D Systems, Lille, France).
Statistical analysis
The statistical significance relationship between expression of
VEGF-A or PAIP2 and clinicopathological parameters was assessed
using w
2 test confirmed by Fisher’s exact test. Correlation between
VEGF-A and PAIP2 expression was examined using the Pearson’s
test confirmed by Spearman rank test. Overall survival was defined
as the time between diagnosis and death due to any cause (in our
study, only one patient died from another cause than HNSCC
cancer). Progression-free survival was defined as the time between
diagnosis and the first clinical or pathological evidence of local or
distant recurrent disease or patient death. Refractory cancers
under treatment were considered to be in progression at the date
of diagnosis. Metastatic-free survival was defined as the time
between diagnosis and the first clinical or pathological evidence of
metastatic recurrent disease. Probabilities of progression-free and
overall survival were estimated using the Kaplan–Meier method
and differences were analysed using the log-rank test. The role of
each possible prognostic factor and their combined effects in
predicting progression-free and overall survival were analysed
using the Cox proportional hazards survival model. Data were
considered statistically significant if P-values were less than or
equal to 0.05. All statistical tests were two-sided. For statistical
evaluation, the R 2.0.1 software was used (Ihaka and Gentleman,
1996).
RESULTS
VEGF-A expression and analysis of the correlation to
clinicopathological factors
We determined the level of VEGF-A expression, by immunoassay,
in cytosols from 54 human head and neck tumours. We observed
that VEGF-A is expressed in nearly all tumours (98.3%). Median
VEGF-A is 830pg mg
 1 of protein (undetectable to 7285pg mg
 1
of protein).
For evaluation of HNSCC, several clinicopathological para-
meters were used, such as the clinical stage, the presence of lymph
node metastases (nodal status) and the degree of tumour
differentiation (differentiation stage). Using univariate analysis,
we investigated the correlation between VEGF-A expression and
these established clinicopathological tumour parameters. As
shown in Table 2, VEGF-A expression significantly correlates with
the tumour differentiation stage (P¼0.050). Tumours with poor
differentiation express higher VEGF-A levels (Xmedian) than
highly differentiated tumours. No significant association between
the clinical stage or nodal status and VEGF-A expression in
tumour tissues was found (Table 2).
VEGF-A expression is an independent prognostic factor for
progression-free survival and overall survival
To investigate whether VEGF-A expression was associated with the
outcome of patients with HNSCC in our study, survival analysis
were performed on progression-free and overall survival of the 54
patients. In total 26 patients (48%) experienced disease recurrence
and 35 (65%) died during the follow-up period. It is noteworthy
Table 2 Univariate analysis of VEGF-A expression and the various
clinicopathological factors
VEGF-A
Variable Number of patients oMedian XMedian P-value
Clinical stage NS
T1–T2 17 8 (47%) 9 (53%)
T3–T4 37 19 (51%) 18 (49%)
Nodal stage NS
N0 18 8 (44%) 10 (56%)
N+ 36 19 (53%) 17 (47%)
Differentiation stage 0.05
High 14 9 (64%) 5 (36%)
Moderate 18 9 (50%) 9 (50%)
Low 21 8 (38%) 13 (62%)
NS: not significant; VEGF-A: Vascular endothelial growth factor A.
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sthat patients who exhibited high VEGF-A levels (Xmedian) had a
significantly higher rate of disease recurrence (P¼0.014) and
death (P¼0.0006) (data not shown).
Table 3 and Figure 1C and D show in univariate survival
analysis, that VEGF-A expression is a factor of poor prognosis for
progression-free survival (P¼0.001), as well as for overall survival
(P¼0.003). Interestingly, VEGF-A expression appears as a
prognostic factor of metastatic-free survival (P¼0.002) but not
of local recurrence-free survival (P¼0.37) (data not shown).
Furthermore, the clinical stage and nodal status, both known as
poor prognostic factors for patient’s outcome, are, in our study,
also significantly correlated to overall survival (P¼0.020 and
0.050, respectively; Table 3, Figure 1A and B). The clinical stage
also correlates to progression-free survival (P¼0.03, Table 3) and
patient age is another prognostic parameter of progression-free
and overall survival (Table 3).
Table 3 Univariate analysis (Kaplan–Meier) on progression-free survival and overall survival of all patients according to patient age, clinical stage, nodal
status and VEGF-A expression
Progression-free survival Overall survival
Variable
Nb of
patients
Nb of
events
a
Median survival
time (mo) P-value
Nb of
patients
Nb of
events
a
Median survival
time (mo) P-value
Patient age o1 10
 3 0.030
o70 years 47 30 26.1 47 29 36.7
X70 years 7 7 6.0 7 6 8.2
Clinical stage 0.03 0.020
T1–T2 17 9 55.4 17 7 58.4
T3–T4 37 28 10.8 37 28 22.4
Nodal status NS 0.050
N0 18 10 30.7 18 8 Not reached
N+ 36 27 13.8 36 27 23.4
VEGF-A
expression
0.001 0.003
omedian 27 12 53.2 27 11 62.3
XMedian 27 25 10.7 27 24 18.7
aEvent for progression-free survival corresponds to the onset of local or distant recurrent disease. Event for overall survival corresponds to patient’s death. mo: months, Nb:
number, NS: not significant; VEGF-A, Vascular endothelial growth factor A.
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Figure 1 Univariate survival analysis investigating the impact of clinical stage (A), nodal status (B) or VEGF-A expression (C) on overall survival of patients
with head and neck carcinomas. Graph D illustrates the impact of VEGF-A expression on progression-free survival.
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clinical stage or nodal status, in term of progression-free and
overall survival, were then analysed in a multivariate Cox
regression model (Table 4). VEGF-A expression is identified as
an independent prognostic parameter for both progression-free
survival and overall survival (P¼0.001 and 0.0004, respectively;
Table 4). Similar results are obtained for clinical stage on
progression-free and overall survivals (P¼0.01 and 0.002,
respectively; Table 4). We also found that patient age has an
independent prognostic impact on progression-free survival
(P¼0.004; Table 4). Conversely, inclusion of neither patient age
nor nodal status in the overall survival analysis, added significant
independent prognostic information (P¼0.08 and 0.13, respec-
tively, Table 4).
PAIP2 strongly regulates VEGF-A expression in a human
pharynx carcinoma cell line
In a previous study, we demonstrated that the Poly(A) binding
protein-Interacting Protein 2 (PAIP2) is a strong regulator of
VEGF-A mRNA expression in a Chinese hamster fibroblast-
derived cell line as well as in two different human tumour cell
lines derived from epidermoid carcinoma (A-431) and cervix
adenocarcinoma (HeLa) (Onesto et al, 2004). By interacting with
the 30untranslated region of VEGF-A mRNA, PAIP2 stabilises this
mRNA, leading to an increase in VEGF-A expression (Onesto et al,
2004).
Prior to analysis for a potential correlation between PAIP2 and
VEGF-A expression in the 54 HNSCC specimens, we first checked
whether the effect of PAIP2 on VEGF-A expression also occurs in a
head and neck carcinoma cell line. To this end, we silenced PAIP2
expression by RNA interference in Detroit 562 cells derived from a
human pharynx carcinoma. It is noteworthy that these cells secrete
higher VEGF-A levels than those secreted by HeLa and A-431 cells
(Detroit 562 cells: 710071410pg of VEGF-A ml 1 10
 6cells
(n¼3); HeLa cells: 37767781pg ml 1 10
 6 cells (n¼3) and
A-431 cells: 624271539pg ml 1 10
 6 cells (n¼2)).
Detroit 562 cells were transfected twice with four different
PAIP2-targeting siRNAs or an irrelevant control siRNA, and
analysed 48h following the second transfection. In contrast to the
unchanged level of ERK2 used as a loading control, PAIP2 is
efficiently depleted by siRNA (a mean of 96% of inhibition),
whatever the specific-siRNA sequence used (Figure 2A). Moreover,
in conditions where PAIP2 is specifically silenced by siRNA,
expression of the VEGF-A mRNA is strongly reduced, as illustrated
in Figure 2B, upper panel. Quantification of these results shows an
approximate 60% decrease of VEGF-A mRNA levels in cells treated
with PAIP2 siRNA sequences 1–3 and a 46% reduction with PAIP2
siRNA sequence 4 (Figure 2B, lower panel). Furthermore, as shown
in Figure 2C, the PAIP2-mediated decrease in VEGF-A expression
not only occurs at the mRNA level but also at the protein level with
an approximate 50% inhibition of secreted VEGF-A when PAIP2 is
silenced. Hence, PAIP2 strongly regulates VEGF-A expression in a
head and neck carcinoma cell line.
Positive correlation between PAIP2 and VEGF-A
expression in human head and neck tumour specimens
We determined PAIP2 expression by Western blotting in cytosols
from the 54 HNSCC specimens. Poly (A) binding protein-
interacting proteing 2 is present in nearly all tumours (98.3%)
and is expressed at various levels in the different tumour
specimens (data not shown). Median PAIP2 is 0.712 arbitrary
units (a.u.), (undetectable to 2.470a.u).
We then investigated whether PAIP2 expression is associated
with VEGF-A expression in the human tumour samples. We found
a statistically significant positive correlation between PAIP2 and
VEGF-A expression (P¼0.0018 – data not shown).
By univariate analysis, we investigated the correlation between
PAIP2 expression and clinicopathological tumour parameters.
Concerning the clinical stage, 59% of the T1–T2 patients (n¼17)
show high PAIP2 levels (Xmedian) vs 49% of the T3–T4 patients
(n¼34). For nodal status, high levels of PAIP2 (Xmedian) are
expressed in 50% of the patients without nodal metastases (n¼18)
vs 53% of node positive patients (n¼36). Concerning the
differentiation stage, high PAIP2 levels (Xmedian) are distributed
as follows: high (14 patients – 57%), moderate (18 patients – 56%)
and low (21 patients – 43%). No statistical significance was found
between all these clinicopathological variables and the degree of
PAIP2 expression in tumour tissues (data not shown).
Similar statistically insignificant results were obtained between
PAIP2 levels and patient’s progression-free survival (P¼0.80) or
overall survival (P¼0.59) (data not shown). Hence, despite its
strong correlation with VEGF-A protein levels, PAIP2 expression is
neither a prognostic factor for tumour progression nor for
patient’s outcome in the 54 human HNSCC analyzed.
DISCUSSION
In this study, we investigated in HNSCC the expression pattern and
prognostic significance of VEGF-A levels as well as levels of a
VEGF-A regulatory protein, the Poly(A) binding protein-Inter-
acting Protein 2 (PAIP2).
We have shown that VEGF-A expression is significantly
associated with the tumour differentiation stage, poorly differ-
entiated tumours expressing higher VEGF-A levels than highly
differentiated tumours. In a recently published meta-analysis in
HNSCCs, Kyzas et al (2005a) have described a trend towards a
correlation of VEGF positivity with poor histological differentia-
tion. Our study provides the conclusive proof that there is a strong
correlation between VEGF-A expression and tumour differentia-
tion in head and neck carcinomas. Prior retrospective studies,
except for the recent meta-analysis (Kyzas et al, 2005a), did not
show any correlation between those two parameters (Salven et al,
1997; Maeda et al, 1998; Mineta et al, 2000; Tae et al, 2000; Do et al,
2004; Kyzas et al, 2005b). The observed difference between all the
studies could be explained by a number of factors, including
heterogeneity in head and neck tumour populations, biased
selection of patients and method of detection of VEGF-A protein
Table 4 Multivariate analysis (Cox model) on progression-free survival and overall survival of all patients
Progression-free survival Overall survival
Variable RR 95% CI of RR P-value RR 95% CI of RR P-value
Patient age o70 years/X70years 4.40 (1.75–11.08) 0.004 — — NS
Clinical stage (T1–T2/T3–T4) 2.65 (1.17–6.0) 0.012 3.44 (1.45–8.17) 0.002
Nodal status (N0/N+) — — — — — NS
VEGF-A expression (o/X median) 3.16 (1.54–6.48) 0.001 3.61 (1.70–7.65) 0.0004
RR: relative risk, CI: confidence interval, NS: not significant; VEGF, Vascular endothelial growth factor A.
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retrospective study. It should be noted that in our study, we
measured VEGF-A expression using a quantitative method (ie
ELISA), in contrast to all previous reports (except one (Mineta
et al, 2000)), in which VEGF-A protein levels have only been
measured by a semiquantitative evaluation method (i.e. immuno-
histochemistry). A similar variability in findings between different
studies is also observed for the association of VEGF-A expression
with clinical stage or nodal status. Some reports (Salven et al, 1997;
Maeda et al, 1998; Neuchrist et al, 1999; Do et al, 2004), including
our study, show no correlation between VEGF-A protein levels and
these clinicopathological parameters, whereas others reported a
relationship (Eisma et al, 1999; Mineta et al, 2000; Tae et al, 2000;
Lim et al, 2003). These conflicting results highlight the necessity to
perform retrospective studies using reliable methodology (pre-
ferentially quantitative) and a large cohort of patients.
Consistent with other findings (Eisma et al, 1997; Eisma et al,
1999; Mineta et al, 2000, 2002; Smith et al, 2000; Kyzas et al,
2005a,b), we showed that high VEGF-A protein levels (Xmedian)
predicted a higher rate of disease recurrence and shorter
progression-free interval. Moreover, tumours expressing high
VEGF-A levels are also more likely to recur distantly than tumours
with low VEGF-A levels (omedian). Multivariate analysis
identified VEGF-A expression as an independent prognostic factor
for progression-free survival and distant recurrence-free survival.
Several studies have shown that VEGF-A, as well as VEGF-C, are
upregulated in head and neck cancers, thus stimulating prolifera-
tion of vascular and lymphatic endothelial cells, and increasing
vessel permeability (Rogers et al, 2005). The enhanced angiogenic
activity could sustain growth of the primary tumour, potentiate
dissemination and also support the establishment of micrometas-
tases. This is consistent with the strong association observed in
this study between VEGF-A expression and distant recurrence.
We also demonstrated that VEGF-A protein levels are closely
associated to overall survival. Subsequently, multivariate analysis
showed that VEGF-A expression is, in our study, an independent
prognostic factor for overall survival. Two other studies have
reported similar results: patients with tumours expressing high
levels of VEGF-A have a shorter overall survival than those with
tumours expressing low VEGF-A levels, and the impact of VEGF-A
is not a combined effect with other markers of poor prognosis
(Smith et al, 2000; Lim et al, 2003). Taken together, the results of
VEGF-A implication on distant recurrence-free and overall
survival support the hypothesis that high VEGF-A levels predict
aggressive disease.
Vascular endothelial growth factor-A expression is tightly
controlled, its regulation occurring at several levels of gene
expression: transcription, mRNA stability and translation. We
previously identified a new protein partner of the VEGF-A mRNA,
the latter being a labile mRNA. This new VEGF-A mRNA-binding
protein, called PAIP2, stabilises VEGF-A mRNA, thus contributing
to an increase in VEGF-A secretion (Onesto et al, 2004). The
significant association observed in this study between VEGF-A and
PAIP2 protein levels in human head and neck carcinomas supports
the data we obtained in several tumour cell lines (Onesto et al,
2004), including a pharynx carcinoma cell line (this report). It also
suggests that VEGF-A expression could be closely controlled by
PAIP2 in human tumour tissue. Interestingly, VEGF-A expression
is also correlated to PAIP2 protein levels in human breast cancer
specimens (Onesto C., unpublished results), bringing forward the
importance of PAIP2 in regulating VEGF-A expression in human
cancers. It would be interesting to compare PAIP2 and VEGF-A
protein levels measured in malignant tissues to their normal
homologues, in order to determine whether they also vary in
parallel in a normal context. Increased expression of VEGF-A has
been demonstrated in HNSCC cell lines, xenografts and clinical
specimens (Rogers et al, 2005). We could imagine that any
dysregulation of PAIP2 expression could explain the abnormal
VEGF-A protein levels in a tumour context. Thus, the regulation of
VEGF-A overexpression in malignant head and neck carcinomas
may provide an interesting example for a possible contribution of
dysregulation of mRNA stability to the progression of cancer.
However, in contrast to VEGF-A, PAIP2 expression is not
associated to patient’s outcome. Thus, despite its significant
influence on VEGF-A expression in HNSCC, PAIP2 is insufficient
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Figure 2 Silencing of PAIP2 by RNA interference inhibits VEGF-A
expression in a human pharynx carcinoma cell line. (A) Total protein
extracts from Detroit 562 cells transiently transfected twice with siRNAs
against PAIP2 or GFP, were analysed by Western blotting using a polyclonal
anti-PAIP2 antibody. The amounts of ERK2 are shown as a loading control.
(B) Total RNA extracted from the same cells was subjected to Northern
blotting analysis for VEGF-A mRNA expression (upper panel). The arrows
point to the different VEGF-A isoforms. 36B4 RNA is shown as a loading
control. The levels of VEGF-A mRNA were quantified by phosphorImaging
analysis (lower panel). The values are normalised to 36B4 RNA. Values
obtained with the control siRNA are taken as 100%. The data shown
represent the means and standard errors of two independent experiments.
(C) Tissue culture supernatants from the same cells were analysed using a
human VEGF-A specific ELISA. The values are normalised to the cell
number. Values obtained with the control siRNA are taken as 100%. The
data shown represent the means and standard errors of two independent
experiments each performed in triplicate.
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sto confer to VEGF-A its impact on poor prognosis. Hence, PAIP2 is
probably not the only protein that regulates VEGF-A expression in
HNSCC. We hypothesise that other factors, which also regulate
VEGF-A expression, will be responsible of VEGF-A impact on poor
prognosis. It would be informative to also analyse the potential
correlation of VEGF-A status with the expression of HuR, another
VEGF-A mRNA-stabilising protein (Levy et al, 1998), which has
also been described in different types of human cancers to be
related to poor tumour prognosis (Denkert et al, 2004a,b). Other
elements, particularly implicated in tumorigenesis and considered
as prognostic factors in HNSCC may also play a role in VEGF-A
regulation, such as the hypoxia-inducible factor (HIF)-1 alpha, the
product of the tumour suppressor gene p53, the Epidermal Growth
Factor Receptor (EGFR) or the cyclooxygenase-2 (COX-2) (Quon
et al, 2001; Cohen, 2004). Furthermore, strong correlations
between these proteins and VEGF-A expression have been
identified in head and neck cancers (O-Charoenrat et al, 2000;
Gallo et al, 2001; Lim et al, 2003; Kimura et al, 2004). It would be
interesting to analyse possible associations of these molecular
markers with VEGF-A status in our study.
The results of this study, coupled with the existing literature,
suggest that patients with tumours with high VEGF-A protein
levels may be at a greater risk of poor progression-free survival,
poor overall survival and metastatic disease. Hence, the VEGF-A
status could emerge as an important factor in establishing
prognosis and selecting treatment modalities for HNSCC. Anti-
angiogenic targeted therapies may positively impact on treatment
of HNSCC. At present, bevacizumab, a humanised monoclonal
antibody that targets VEGF-A, is undergoing clinical evaluation (in
association with EGFR-targeted drugs) in HNSCC (Caponigro et al,
2005). In the future, it would be helpful in clinical trials to
determine whether VEGF-A could serve not only as a prognostic
marker in head and neck carcinomas, but also as a predictive tool
for the most efficient response to treatment.
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